[Identification of potential influencing factors associated with elimination of migraine headache in patients with PFO after percutaneous closure].

Objective: To recognize the potential factors that contribute to the eradication of migraine headache in patients with patent foramen ovale (PFO) at one year after percutaneous closure. Methods: A prospective cohort study was conducted, which enrolled patients diagnosed with migraines and PFO at the Department of Structural Heart Disease, First Affiliated Hospital of Xi'an Jiaotong University between May 2016 and May 2018. The patients were segregated into two groups based on their response to treatment, and one group showed elimination of migraines while another did not. Elimination of migraines was defined as a Migraine Disability Assessment Score (MIDAS) score of 0 at one year postoperatively. Least Absolute Shrinkage and Selection Operator (LASSO) regression model was utilized to identify the predictive variables for migraine elimination post-PFO closure. Multiple logistic regression analysis was employed to determine the independent predictive factors. Results: The study enrolled a total of 247 patients, with an average age of (37.5±13.6) years, comprising 81 male individuals (32.8%). One year after closure, 148 patients (59.9%) reported eradication of their migraines. Multivariate logistic regression analysis revealed that migraine with or without aura (OR=0.003 9, 95%CI 0.000 2-0.058 7, P=0.000 18), a history of antiplatelet medication use (OR=0.088 2, 95%CI 0.013 7-0.319 3, P=0.001 48) and resting right-to-left shunt (RLS) (OR=6.883 6, 95%CI 3.769 2-13.548 0, P<0.001) were identified as independent predictive factors for elimination of migraine. Conclusion: Migraine with or without aura, a history of antiplatelet medication use, and resting RLS are the independent prognostic factors associated with elimination of migraine. These results provide important clues for clinicians to choose the optimal treatment plan for PFO patients. However, further studies are needed to confirm these findings.

[An in vitro and in vivo study of antitumor effects of rHTNF-alpha on human ovarian cancer].

We examined the cytotoxic activities of recombinant human tumor necrosis factor (rHTNF-alpha) and five chemotherapeutic agents, CTX, 5-Fu, VCR, DDP, KSM, against two human ovarian cancer cell lines, OVCAR3 and CAOV3, using the MTT assay. The results showed that cytotoxicities of rHTNF-alpha at 5 x 10-5 x 10(4) u/ml against OVCAR3 cell line for 24 h exposure were from 14.2 +/- 6.8% to 67.2 +/- 3.0%, and those against CAOV3 cell line were from 8.2 +/- 4.3% to 60.9 +/- 1.3%. The cytotoxic effects of all five chemotherapeutic agents against the two cell lines were much lower than that of rHTNF-alpha. Further, we studied the combined anticancer potential of rHTNF-alpha with chemotherapeutic agents against the two cell lines. Various degrees of synergism in cytotoxicities of DDP or KSM in combination with rHTNF-alpha were observed. The cytotoxic effect of rHTNF-alpha on CAOV3 cell were also morphologically observed under phase contrast and electron microscope. Based on experiment in vitro, the in vivo anticancer activity of rHTNF-alpha alone or in combination with KSM was examined against human ovarian cancer OVCAR3 subcutaneously transplanted in nude mice. After 8 weeks of treatment, a statistically significant difference of mean tumor volume was found between the control group and groups that received rHTNF-alpha or rHTNF-alpha plus KSM (P < 0.01).

[Cytotoxicity of recombinant human tumor necrosis factor (rHTNF) alone and in combination with chemotherapeutic agents on human ovarian cancer cells].

The cytotoxic activities of recombinant human tumor necrosis factor (rHTNF) and five chemotherapeutic agents, CTX, 5-FU, VCR, DDP, KSM, against two human ovarian cancer cell lines, OVCAR3 and CAOV3, using the MTT assay were studied. The result showed that cytotoxicities of rHTNF at 5 x 10(4)-5 x 10(7) U/L against CAOV3 cell line for 24h exposure were from 14.2% +/- 6.8% to 67.2% +/- 3.0%, and that against CAOV3 cell line were from 8.2% +/- 4.3% to 60.9% +/- 1.3%. The cytotoxic effects of all five chemotherapeutic agents against the two cell lines were much lower than that of rHTNF. Various degrees of synergistic enhancement cytotoxicities of DDP or KSM in combination with rHTNF were assessed. Especially, distinct synergistic effects of a low dose, 50kU/L, or rHTNF with nearly all concentration (10(-4)-10(-1) mg/L) of KSM were obtained on the two cell lines.